Terada T, Ohta T, Sasaki M, Nakanuma Y, Kim Y S
Departments of Pathology (II) and Surgery (II), Kanazawa University Scool of Medicine, Japan.
J Pathol. 1996 Oct;180(2):160-5. doi: 10.1002/(SICI)1096-9896(199610)180:2<160::AID-PATH625>3.0.CO;2-A.
The epithelial expression of apomucins MUC1, MUC2, MUC3, and MUC5/6 was examined in normal pancreas and in pancreatic lesions, using immunohistochemical methods. In normal pancreas (n = 5), MUC1 apomucin was expressed in ducts and some acini, but there was no expression of MUC2, MUC3, or MUC5/6. In chronic pancreatitis (n = 5), MUC1 apomucin was expressed, but expression of the other apomucins was not noted. However, mucous hyperplastic foci of pancreatic ducts expressed MUC5/6 apomucin in 2/5 cases (40 percent). In intraductal papillary-mucinous neoplasm (IPMN) of the pancreas (n = 9), MUC1, MUC2, MUC3, and MUC5/6 apomucins were expressed in 8/9 (89 percent), 0/9 (0 per cent), 4/9 (44 per cent), and 9/9 (100 per cent) case, respectively. In pancreatic mucinous cystadenoma (n = 8), MUC1, MUC2, MUC3, and MUC5/6 apomucins were expressed in 7/8 (88 percent), 0/8 (0 percent), (25 percent), and 3/8 (38 percent) cases, respectively. In invasive ductal adenocarcinoma of the pancreas (n = 25), expression of MUC1, MUC2, MUC3, and MUC5/6 apomucins was found in 25/25 (100 percent), 1/25 (4 percent), 20/25 (80 percent), and 24/25 (96 percent) cases, respectively. Atypical mucous duct hyperplasia near cancer cells consistently expressed MUC1 apomucin and occasionally expressed MUC3 and MUC5/6. In positive cases, MUC1 apomucin expression was noted in the cell membrane facing the ductal or neoplastic lumina, while expression of MUC2, MUC3, and MUC5/6 apomucins was found in the cytoplasm. These results suggest that MUC3 and MUC5/6 apomucins newly emerge during the neoplastic transformation of pancreatic mucinous cystadenoma and IPMN and during pancreatic ductal carcinogenesis, while MUC1 apomucin remains positive and MUC2 apomucin remains almost negative during neoplastic transformation.
采用免疫组化方法检测了正常胰腺及胰腺病变组织中脱辅基粘蛋白MUC1、MUC2、MUC3和MUC5/6的上皮表达情况。在正常胰腺（n = 5）中，MUC1脱辅基粘蛋白在导管和部分腺泡中表达，但未检测到MUC2、MUC3或MUC5/6的表达。在慢性胰腺炎（n = 5）中，MUC1脱辅基粘蛋白有表达，但未观察到其他脱辅基粘蛋白的表达。然而，胰腺导管的黏液增生灶在2/5例（40%）中表达MUC5/6脱辅基粘蛋白。在胰腺导管内乳头状黏液性肿瘤（IPMN，n = 9）中，MUC1、MUC2、MUC3和MUC5/6脱辅基粘蛋白的阳性表达率分别为8/9（89%）、0/9（0%）、4/9（44%）和9/9（100%）。在胰腺黏液性囊腺瘤（n = 8）中，MUC1、MUC2、MUC3和MUC5/6脱辅基粘蛋白的阳性表达率分别为7/8（88%）、0/8（0%）、2/8（25%）和3/8（38%）。在胰腺浸润性导管腺癌（n = 25）中，MUC1、MUC2、MUC3和MUC5/6脱辅基粘蛋白的阳性表达率分别为25/25（100%）、1/25（4%）、20/25（80%）和24/25（96%）。癌细胞附近的非典型黏液导管增生始终表达MUC1脱辅基粘蛋白，偶尔表达MUC3和MUC5/6。在阳性病例中，MUC1脱辅基粘蛋白在面向导管或肿瘤管腔的细胞膜上表达，而MUC2、MUC3和MUC5/6脱辅基粘蛋白在细胞质中表达。这些结果表明，MUC3和MUC5/6脱辅基粘蛋白在胰腺黏液性囊腺瘤和IPMN的肿瘤转化过程以及胰腺导管癌发生过程中重新出现，而MUC1脱辅基粘蛋白在肿瘤转化过程中保持阳性，MUC2脱辅基粘蛋白几乎保持阴性。
